YOLFTbeta
Genmab AS

Genmab AS

GMAB · NASDAQ · Healthcare / Biotechnology

51.37USD-0.37 (-0.72%)

Price History

Full chart

Market Stats

Previous Close51.74
Open51.22
Day Range50.68 – 51.62
52-Week Range23.62 – 59.97
Volume3.73M
Market Cap32.98B
P/E (TTM)45.84
Forward P/E22.94
EPS1.17
Dividend Yield0.00%
Beta0.52
50-Day Avg39.18
200-Day Avg31.05

About

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jan G.J. van de Winkel Ph.D.
  • Employees2.97K
  • HeadquartersCarl Jacobsens Vej 30, Copenhagen, Denmark, 2500, USA
  • Websitehttps://www.genmab.com

Leadership

  • Dr. Jan G.J. van de Winkel Ph.D.Co-Founder, President & CEO · b. 1961
  • Mr. Anthony Pagano CPAExecutive VP & CFO · b. 1978
  • Mr. Rayne WallerExecutive VP & Chief Technical Operations Officer · b. 1968
  • Mr. Gregory David Emil MuellerExecutive VP, General Counsel & Chief Legal Officer · b. 1971
  • Mr. Christopher CozicExecutive VP & Chief People Officer · b. 1978
  • Dr. Martine J. van Vugt Ph.D.Executive VP & Chief Strategy Officer · b. 1971
  • Mr. Martin SchultzSenior Director, Head of Development Business Partnership & Strategy and Director · b. 1975
  • Dr. Judith V. Klimovsky M.D.Executive VP & Chief Development Officer · b. 1958
  • Dr. Tahamtan Ahmadi M.D., Ph.D.Executive VP, Chief Medical Officer & Head of Experimental Medicines · b. 1973
  • Dr. Mijke Zachariasse Ph.D.VP, Head of Antibody Research Materials & Director · b. 1973

Financials

Income Statement

Currency: DKK2002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-68.33M4.10M98.50M135.55M529.54M692.30M586.08M582.08M350.94M484.64M663.57M850.38M1.13B1.82B2.37B3.03B5.37B10.11B8.42B14.51B16.47B21.53B3.72B
Growth (%)---94.00%+2301.98%+37.60%+290.67%+30.74%-15.34%-0.68%-39.71%+38.10%+36.92%+28.15%+33.24%+60.29%+30.25%+27.89%+77.38%+88.43%-16.75%+72.33%+13.57%+30.67%-82.70%
Cost of Revenue------48.81M-582.51M532.51M-11.67M-00000-00226.00M985.00M309.24M
Gross Profit-68.33M4.10M98.50M135.55M529.54M696.30M586.08M-435.00K-181.57M484.64M663.57M850.38M1.13B1.82B2.37B3.03B5.37B10.11B8.42B14.51B16.25B20.54B3.41B
Gross Margin-100.00%100.00%100.00%100.00%100.00%100.58%100.00%-0.07%-51.74%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%98.63%95.42%91.69%
Operating Expense--273.88M-437.17M526.43M607.76M966.67M1.42B1.08B160.25M67.85M601.32M594.32M585.21M402.66M763.29M1.02B1.64B2.73B3.80B5.46B8.24B10.93B13.84B2.16B
Operating Income-483.08M342.21M441.27M-427.92M-472.21M-437.13M-728.49M-498.03M-160.69M-249.42M-116.68M69.25M265.18M730.38M1.05B1.34B1.38B2.64B6.31B2.95B6.27B5.32B6.70B1.25B
Operating Margin-500.85%10760.13%-434.42%-348.38%-82.55%-105.23%-84.98%-27.61%-71.07%-24.08%10.44%31.18%64.46%57.97%56.83%45.63%49.16%62.44%35.08%43.21%32.30%31.14%33.60%
EBITDA669.75M474.56M537.46M-360.46M-419.70M-317.72M-516.46M-77.11M-61.76M-192.75M-96.25M80.92M313.73M789.47M1.17B1.44B1.70B3.00B6.17B4.18B7.35B6.00B9.70B1.34B
EBITDA Margin-694.55%13105.49%-365.93%-309.64%-60.00%-74.60%-13.16%-10.61%-54.92%-19.86%12.19%36.89%69.68%64.50%60.72%56.20%56.00%61.05%49.66%50.64%36.42%45.05%35.91%
Net Income-479.33M-327.11M-415.21M-393.59M-438.24M-383.37M-965.09M-1.01B-321.46M-596.37M-487.12M112.36M301.30M763.51M1.19B1.10B1.47B2.17B4.76B2.96B5.45B4.35B7.84B963.76M
Net Income Margin--478.75%-10124.65%-399.56%-323.31%-72.40%-139.40%-172.46%-55.23%-169.94%-100.51%16.93%35.43%67.39%65.36%46.65%48.66%40.37%47.06%35.13%37.59%26.42%36.44%25.89%
R&D396.23M345.98M373.33M304.10M359.95M618.50M1.42B935.36M--536.70M527.58M505.68M487.66M660.88M874.28M1.43B2.39B3.14B4.18B5.56B7.63B9.75B1.56B
R&D as % of Total Revenue-506.37%9103.39%308.72%265.56%116.80%205.51%159.60%--110.74%79.51%59.46%43.04%36.39%36.96%47.31%44.47%31.03%49.67%38.35%46.32%45.28%41.91%
Interest Expense100.37M83.71M68.58M1.35M1.01M1.09M220.83M181.10M39.65M2.03M2.72M3.33M4.05M118.00K213.00K2.00M417.00K7.00M10.00M13.00M21.00M27.00M120.00M61.05M
Interest Expense % of Total Revenue-122.51%1672.30%1.37%0.74%0.21%31.90%30.90%6.81%0.58%0.56%0.50%0.48%0.01%0.01%0.08%0.01%0.13%0.10%0.15%0.14%0.16%0.56%1.64%

Balance Sheet

Currency: DKK2002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.58B1.18B1.27B1.37B1.80B3.96B3.26B2.22B2.48B1.56B1.69B1.73B2.87B3.90B5.24B6.60B8.46B15.14B21.14B24.63B30.12B35.29B45.81B12.84B
Total Liabilities183.97M93.67M90.92M251.66M197.05M1.08B1.07B924.34M1.40B1.08B1.31B1.07B833.74M415.83M411.54M330.75M446.64M1.10B2.02B2.43B2.84B3.68B9.11B7.01B
Total Equity1.40B1.09B1.18B1.12B1.61B2.88B2.19B1.30B1.08B486.42M383.19M659.52M2.03B3.49B4.83B6.27B8.01B14.05B19.12B22.20B27.28B31.61B36.70B5.83B
Cash252.95M308.92M419.57M381.35M429.07M131.75M70.01M460.74M100.95M65.20M66.99M168.13M359.09M873.99M307.02M1.35B532.91M3.55B7.26B8.96B9.89B14.87B9.86B1.71B
Total Debt13.78M24.14M29.00M23.04M18.21M15.67M14.70M24.94M133.72M11.85M5.66M2.48M355.00K118.00K61.61M00181.00M319.00M425.00M597.00M770.00M1.03B5.43B
Net Debt-239.17M-284.78M-390.56M-358.31M-410.87M-116.09M-55.31M-435.80M32.77M-53.35M-61.33M-165.65M-358.73M-873.87M-307.02M-1.35B-532.91M-3.37B-6.94B-8.53B-9.30B-14.10B-8.83B3.71B

Cash Flow

Currency: DKK2002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-308.32M-302.36M-367.70M-208.64M-379.62M505.90M-513.33M-570.06M268.17M-437.23M70.92M-128.00M132.67M311.45M327.72M1.59B1.01B1.33B6.43B2.23B3.91B7.38B7.77B1.19B
Investing Cash Flow238.55M361.90M-25.07M-127.55M-451.37M-2.36B460.10M974.73M-738.50M514.75M-416.34M66.95M-1.01B-480.88M-1.01B-667.57M-1.78B-1.98B-2.35B-961.00M-2.76B-1.28B-9.91B-5.65B
Financing Cash Flow156.85M-3.57M503.41M297.36M879.03M1.56B25.29M-6.64M-7.00M-6.09M357.81M151.66M1.04B643.09M91.19M214.91M-70.90M3.66B71.00M-420.00M-789.00M-606.00M-3.92B4.79B
Capital Expenditure100.82M14.70M8.27M2.43M1.94M12.84M53.02M16.78M10.11M7.21M9.00M10.37M75.44M135.39M33.11M88.51M477.37M111.00M307.00M252.00M317.00M376.00M187.00M37.03M
Free Cash Flow-409.14M-317.07M-375.96M-211.08M-381.56M493.06M-566.35M-586.84M258.06M-444.43M61.92M-138.36M57.23M176.06M294.61M1.50B537.42M1.22B6.13B1.98B3.60B7.00B7.58B1.15B
Dividends Paid-------------00009.00M115.00M135.00M280.00M---
FCF to OCF132.70%104.86%102.25%101.17%100.51%97.46%110.33%102.94%96.23%101.65%87.31%108.10%43.14%56.53%89.90%94.43%52.96%91.63%95.23%88.69%91.90%94.91%97.59%96.88%
Dividend Paid to FCF-------------0.00%0.00%0.00%0.00%0.74%1.88%6.83%7.79%---

Earnings

Report DateAug 18, 2009Nov 10, 2009Mar 3, 2010May 11, 2010Aug 17, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Nov 2, 2016Feb 22, 2017May 11, 2017Aug 9, 2017Nov 8, 2017Feb 21, 2018May 8, 2018Aug 8, 2018Nov 14, 2018Feb 19, 2019May 8, 2019Aug 20, 2019Nov 6, 2019Feb 19, 2020May 6, 2020Aug 12, 2020Nov 11, 2020Feb 23, 2021May 21, 2021Aug 11, 2021Nov 10, 2021Feb 16, 2022May 11, 2022Aug 10, 2022Nov 9, 2022Feb 22, 2023May 10, 2023Aug 3, 2023Nov 7, 2023Feb 14, 2024May 2, 2024Aug 8, 2024Nov 6, 2024Feb 12, 2025May 8, 2025Aug 7, 2025Nov 6, 2025Feb 17, 2026May 7, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate----------------------------------------0.270.363.430.296.430.991.280.230.070.135.300.190.200.200.330.150.290.310.300.140.320.330.280.230.390.450.370.190.370.36
EPS Actual-0.05-0.04-0.16-0.05-0.03-0.31-0.43-0.31-0.03-0.13-0.250.03-0.17-0.060.10-0.090.020.210.32-0.080.470.190.520.040.340.95-0.030.410.460.050.040.000.08-0.000.210.050.070.040.200.020.201.233.410.307.580.130.140.270.080.210.170.100.400.530.130.050.300.460.140.290.320.290.840.310.540.650.210.130.540.56
Surprise-----------------------------------------25.93%241.67%-0.58%3.45%17.88%-86.87%-89.06%17.39%10.65%59.70%-96.79%-47.37%100.00%165.00%-60.61%-66.67%3.45%48.39%-53.33%107.14%0.00%-12.12%200.00%34.78%38.46%44.44%-43.24%-31.58%45.95%55.56%
Timing----------------------------------------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-market

Key Statistics & Ratios

Market Cap32.98B
Enterprise Value35.92B
Trailing P/E45.84
Forward P/E22.94
PEG Ratio7.98
Price / Sales7.68
Price / Book5.21
EPS1.17
Book Value10.01
Revenue (TTM)4.30B
Gross Profit (TTM)3.98B
EBITDA1.36B
Profit Margin16.97%
Operating Margin37.15%
Return on Equity12.07%
Return on Assets8.24%
Shares Outstanding614.95M
Shares Float588.77M
Beta0.52
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 12 analystsTarget 65.01
  • Strong Buy
    10
  • Buy
    1
  • Hold
    1

Ownership Breakdown

Institutions
20.61%
Insiders
0.00%
Retail / Other
79.39%

Top Institutional Holders

  • Paradigm Biocapital Advisors LP
    13.13M2.14%
  • Orbis Allan Gray Ltd
    11.37M1.85%
  • AllianceBernstein L.P.
    8.64M1.41%
  • Deerfield Management Co
    6.87M1.12%
  • Deep Track Capital, LP
    5.65M0.92%
  • Arrowstreet Capital Limited Partnership
    4.98M0.81%
  • BlackRock Inc
    4.67M0.76%
  • Sofinnova Ventures
    4.05M0.66%
  • Renaissance Technologies Corp
    3.52M0.57%
  • Two Sigma Investments LLC
    3.51M0.57%
  • Harding Loevner L.P.
    3.09M0.50%
  • First Trust Advisors L.P.
    2.76M0.45%
  • Citadel Advisors Llc
    2.48M0.40%
  • Qube Research & Technologies
    1.69M0.27%

Top Fund Holders

  • iShares Biotechnology ETF
    4.31M0.70%
  • AllianceBernstein US L/C Growth Eqty MF
    3.95M0.64%
  • American Funds New Perspective A
    3.08M0.50%
  • First Trust NYSE Arca Biotech ETF
    2.64M0.43%
  • Orbis SICAV Intl Eq Inv
    2.21M0.36%
  • Orbis SICAV Global Bal Instl Inv
    1.79M0.29%

Stock Splits

  • May 1, 20185:1